News
We’ve come a long way, fast. Read about our journey.
Totus Medicines is presenting at the American Association for Cancer Research (AACR) Annual Meeting, April 14–19 2023
We are proud to present the following subjects at the AACR Annual Meeting 2023:
- AACR23 Abstract 1 — Development and validation of a pharmacodynamic (PD) assay for TOS-358, the first covalent inhibitor of PI3Kα in clinical development
- AACR23 Abstract 2 — Covalent inhibition of wild-type PI3Kα signaling is required for durable efficacy in PI3Kα mutant cancer cells due to robust re-activation of wild-type PI3Kα signaling
- AACR23 Abstract 3 — TOS-358, a first-in-class covalent PI3Kα inhibitor, demonstrates superior efficacy and does not induce significant hyperglycemia at efficacious doses in multiple animal models
- AACR23 Abstract 4 — A study to evaluate the safety and tolerability of the covalent phosphoinositide-3-kinase (PI3K)-alpha Inhibitor, TOS-358, in adult subjects with select solid tumors
2023
2022
Totus Medicines CEO to Present at Next-Generation Undruggable Conference
PR Newswire
10 11 2022
Totus Medicines Announces New San Francisco Bay Area Headquarters & Expanded Lab Space
PR Newswire
03 31 2022
East Coast biotech company relocates HQ to Emeryville
San Francisco Business Times
03 31 2022
Cambridge biotech relocates to West Coast
Boston Business Journal
03 31 2022
Totus Medicines Hires Corporate Strategy Leader Laura Miller
PR Newswire
03 23 2022
Totus Medicines to Present at 2022 J.P. Morgan HealthCare Conference
PR Newsire
01 11 2022
2021
A breakthrough cancer drug already, and more on the way.